Labeling of phosphorothioate antisense oligonucleotides with yttrium-90

Nuclear Medicine and Biology

Volumn 26, Issue 2, 1999, Pages 239-243

  Watanabe, Naoyuki ^a   Sawai, Hiroaki ^c   Endo, Keigo ^b   Shinozuka, Kazuo ^c   Ozaki, Hiroaki ^c   Tanada, Shuji ^a   Murata, Hajime ^a   Sasaki, Yasuhito ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

N myc gene; Phosphorothioate antisense oligonucleotide; Radiotherapy; SCN Bn EDTA; Yttrium 90

Indexed keywords

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; YTTRIUM 90;

ARTICLE; BASE PAIRING; DRUG SYNTHESIS; GENE ACTIVATION; GENE TARGETING; HYBRIDIZATION; LABELING INDEX; ONCOGENE C MYB; POLYACRYLAMIDE GEL ELECTROPHORESIS; TARGET CELL;

BLOOD PHYSIOLOGY; CELL-FREE SYSTEM; EDETIC ACID; HUMANS; ISOTHIOCYANATES; OLIGONUCLEOTIDES, ANTISENSE; RADIOCHEMISTRY; SEQUENCE ANALYSIS, DNA; THIONUCLEOTIDES; YTTRIUM RADIOISOTOPES;

EID: 0033011868     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00092-4     Document Type: Article

References (15)

1. Brechbiel M.W., Gansow O.A., Atcher R.W., Schlom J., Esteban J., Simpson D.E., Colcher D. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies. Inorg. Chem. 25:1986;2772-2781.
2. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur. J. Nucl. Med. 24:1997;368-371.
3. Dewanjee M.K., Ghafouripour A.K., Kapadvanjwala M., Dewanjee S., Serafini A.N., Lopez D.M., Sfakiankis G.N. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J. Nucl. Med. 35:1994;1054-1063.
4. Guvakova M.A., Yakubov L.A., Vlodavsky I., Tonkinson J.L., Stein C.A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270:1995;2620-2627.
5. 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. Br. J. Cancer. 62:1990;48-51.
6. 99mTc-labeled oligonucleotides. Q. J. Nucl. Med. 40:1996;202-208.
7. Hnatowich D.J., Virzi F., Doherty P.W. DTPA-coupled antibodies labeled with yttrium-90. J. Nucl. Med. 26:1985;503-509.
8. Ho P.T.C., Parkinson D.R. Antisense oligonucleotides as therapeutics for malignant diseases. Semin. Oncol. 24:1997;187-202.
9. Kairemo K.J.A., Tenhunen M., Jekunen A.P. Dosimetry of radionuclide therapy using radiophosphonated antisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetic and tissue distribution data. Antisense Nucleic Acid Drug Dev. 6:1996;215-220.
10. Rosolen A., Whitesell L., Ikegaki N., Kennett R.H., Neckers L.M. Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein ina neuroepithelioma cell line. Cancer Res. 50:1990;6316-6322.
11. Sawai H., Nakamura A., Sekiguchi S., Yumoto K., Endoh M., Ozaki H. Efficient synthesis of new 5-substituted uracil nucleosides useful for linker arm incorporation. J. Chem. Soc. Chem. Commun. 1994;1997-1998.
12. Stanton L.W., Schwab M., Bishop M. Nucleotide sequence of the human N-myc gene. Proc. Natl. Acad. Sci. USA. 83:1986;1772-1776.
13. Tian J.H., Xu B.X., Zhang J.M., Dong B.W., Liang P., Wang X.D. Ultrasound-guided internal radiotherapy using yttrium-90-glass microspheres for liver malignancies. J. Nucl. Med. 37:1996;958-963.
14. Watanabe N., Oriuchi N., Igarashi H., Higuchi T., Yukihiro M., Fukushima Y., Tomiyoshi K., Hirano T., Inoue T., Endo K. Preparation of yttrium-90-labeled human macroaggregated albumin for regional radiotherapy. Nucl. Med. Biol. 24:1997;465-469.
15. Zhang R., Diasio R.B., Lu Z., Jiang Z., Galbraith W.N., Agrawal S. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immuno-deficiency virus type I. Biochem. Pharmacol. 49:1995;929-939.